Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS20100160368 A1
Tipo de publicaciónSolicitud
Número de solicitudUS 12/543,434
Fecha de publicación24 Jun 2010
Fecha de presentación18 Ago 2009
Fecha de prioridad18 Ago 2008
También publicado comoUS8598196, US9271973, US20120083507, US20120264778, US20120283286, US20120289537, US20140323516
Número de publicación12543434, 543434, US 2010/0160368 A1, US 2010/160368 A1, US 20100160368 A1, US 20100160368A1, US 2010160368 A1, US 2010160368A1, US-A1-20100160368, US-A1-2010160368, US2010/0160368A1, US2010/160368A1, US20100160368 A1, US20100160368A1, US2010160368 A1, US2010160368A1
InventoresJefferson J. Gregory
Cesionario originalGregory Jefferson J
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US 20100160368 A1
Resumen
Pharmaceutical Formulations and Methods for the Topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
Imágenes(22)
Previous page
Next page
Reclamaciones(117)
1. A method of topical and/or transdermal administration of imiquimod for treating a dermatological disorder in a mammal, which method comprises:
(a) applying an effective amount of a formulation containing imiquimod on the skin of a mammal once a day at least 3 times a week on 3 different days for at least between about 8 weeks and 12 weeks; and
(b) allowing said imiquimod to remain in contact with the skin for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve the antiviral effect.
2. A method of claim 1, wherein said formulation is applied for 8 weeks.
3. A method of claim 1, wherein said formulation is applied for 9 weeks.
4. A method of claim 1, wherein said formulation is applied for 10 weeks.
5. A method of claim 1, wherein said formulation is applied for 11 weeks.
6. A method of claim 1, wherein said formulation is applied for 12 weeks.
7. A method of claims 1-6, wherein the formulation is applied once a day at least 4 times a week.
8. A method of claims 1-6, wherein the formulation is applied once a day at least 5 times a week.
9. A method of claims 1-6, wherein the formulation is applied once a day at least 6 times a week.
10. A method of claims 1-6, wherein the formulation is applied once a day at least 7 times a week.
11. A method of claims 1-10, wherein the formulation contains from greater than about 1% to about 5% imiquimod.
12. A method of claim 11, wherein the formulation contains about 1.25% imiquimod.
13. A method of claim 11, wherein the formulation contains about 1.5% imiquimod.
14. A method of claim 11, wherein the formulation contains about 1.75% imiquimod.
15. A method of claim 11, wherein the formulation contains about 2% imiquimod.
16. A method of claim 11, wherein the formulation contains about 2.25% imiquimod.
17. A method of claim 11, wherein the formulation contains about 2.5% imiquimod.
18. A method of claim 11, wherein the formulation contains about 2.75% imiquimod.
19. A method of claim 11, wherein the formulation contains about 3% imiquimod.
20. A method of claim 11, wherein the formulation contains about 3.25% imiquimod.
21. A method of claim 11, wherein the formulation contains about 3.5% imiquimod.
22. A method of claim 11, wherein the formulation contains about 3.75% imiquimod.
23. A method of claim 11, wherein the formulation contains about 4.0% imiquimod.
24. A method of claim 11, wherein the formulation contains about 4.25% imiquimod.
25. A method of claim 11, wherein the formulation contains about 4.5% imiquimod.
26. A method of claims 1-25, wherein the dermatological disorder is a viral disease.
27. A method of claim 26, wherein the viral disease is a Type I Herpes simplex infection.
28. A method of claim 26, wherein the viral disease is a Type II Herpes simplex infection.
29. A method of claims 1-25, wherein the dermatological disorder is external genital or perianal warts.
30. A method of claims 1-25, wherein the dermatological disorder is actinic keratosis.
31. A method of claims 1-25, wherein the dermatological disorder is superficial basal cell carcinoma.
32. A method of claims 1-31, wherein the formulation further includes a fatty acid.
33. A method of claim 32, wherein the fatty acid is isostearic acid.
34. A method of claim 32, wherein the fatty acid is oleic acid.
35. A method of claim 32, wherein the fatty acid is super purified oleic acid.
36. A method of claim 32, wherein the fatty acid is linoleic acid.
37. A method of claims 1-36, wherein the formulation is selected from the group consisting of a cream, ointment, gel, foam, lotion and adhesive-coated sheet material.
38. A method of topical and/or transdermal administration of imiquimod to induce interferon biosynthesis in a mammal, which method comprises:
(a) applying an effective amount of a formulation containing imiquimod on the skin of a mammal once a day at least 3 times a week on 3 different days for at least between about 8 weeks and 12 weeks; and
(b) allowing said imiquimod to remain in contact with the skin for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve the antiviral effect.
39. A method of claim 38, wherein said formulation is applied for 8 weeks.
40. A method of claim 38, wherein said formulation is applied for 9 weeks.
41. A method of claim 38, wherein said formulation is applied for 10 weeks.
42. A method of claim 38, wherein said formulation is applied for 11 weeks.
43. A method of claim 38, wherein said formulation is applied for 12 weeks.
44. A method of claims 38-43, wherein the formulation is applied once a day at least 4 times a week.
45. A method of claims 38-43, wherein the formulation is applied once a day at least 5 times a week.
46. A method of claim 38-43, wherein the formulation is applied once a day at least 6 times a week.
47. A method of claim 38-43, wherein the formulation is applied once a day at least 7 times a week.
48. A method of claims 38-47, wherein the formulation contains from greater than about 1% to about 5% imiquimod.
49. A method of claim 48, wherein the formulation contains about 1.25% imiquimod.
50. A method of claim 48, wherein the formulation contains about 1.5% imiquimod.
51. A method of claim 48, wherein the formulation contains about 1.75% imiquimod.
52. A method of claim 48, wherein the formulation contains about 2% imiquimod.
53. A method of claim 48, wherein the formulation contains about 2.25% imiquimod.
54. A method of claim 48, wherein the formulation contains about 2.5% imiquimod.
55. A method of claim 48, wherein the formulation contains about 2.75% imiquimod.
56. A method of claim 48, wherein the formulation contains about 3% imiquimod.
57. A method of claim 48, wherein the formulation contains about 3.25% imiquimod.
58. A method of claim 48, wherein the formulation contains about 3.5% imiquimod.
59. A method of claim 48, wherein the formulation contains about 3.75% imiquimod.
60. A method of claim 48, wherein the formulation contains about 4.0% imiquimod.
61. A method of claim 48, wherein the formulation contains about 4.25% imiquimod.
62. A method of claim 48, wherein the formulation contains about 4.5% imiquimod.
63. A method of claim 38-48, wherein the formulation further includes a fatty acid.
64. A method of claim 63, wherein the fatty acid is isostearic acid.
65. A method of claim 63, wherein the fatty acid is oleic acid.
66. A method of claim 63, wherein the fatty acid is super purified or refined oleic acid.
67. A method of claim 63, wherein the fatty acid is linoleic acid.
68. A method of claims 38-67, wherein the formulation is selected from the group consisting of a cream, ointment, gel, foam, lotion and adhesive-coated sheet material.
69. A method of treating actinic keratosis with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to an area affected with actinic keratosis, once per day for fourteen (14) days, followed by no application for fourteen (14) days, followed by again applying an effective amount of the low dose imiquimod formulation to the area affected with the actinic keratosis once per day for fourteen (14) days for a total of twenty-eight (28) doses, to treat the actinic keratosis.
70. A method of treating actinic keratosis with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 215%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to an area affected with actinic keratosis, once per day for twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective amount of the low dose imiquimod formulation to the area affected with the actinic keratosis once per day for twenty one (21) days for a total of forty-two (42) doses, to treat actinic keratosis.
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to the warts, once per day, each day, for up to about 56 consecutive days or about 8 consecutive weeks or until clearance is observed, which ever occurs earlier to treat the warts.
71. A method of treating warts, such as genital or perianal warts, with low dose ikmiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method, comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to the warts, once per day, each day, for up to about 56 consecutive days or about 8 consecutive weeks or until clearance is observed, which ever occurs earlier to treat the warts.
72. A method of treating a dermatological area affected with a viral disorder with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to an area affected with the viral disorder, once per day for fourteen (14) days, followed by no application for fourteen (14) days, followed by again applying an effective amount of the low dose imiquimod formulation to the virally affected area once per day for fourteen (14) days for a total of twenty-eight (28) doses, to treat the viral disorder.
73. A method of treating a dermatological area affected with a viral disorder with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to an area affected with the viral disorder, once per day for twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective amount of the low dose imiquimod formulation to the virally affected area once per day for twenty one (21) days for a total of forty-two (42) doses, to treat the viral disorder.
74. A method of treating a dermatological area affected with a viral disorder with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to the viral disorder, once per day, each day, for up to about 56 consecutive days or about 8 consecutive weeks or until clearance is observed, which ever occurs earlier to treat the viral disorder.
75. A method of claims 69-74, wherein the viral disease is a Type I Herpes simplex infection.
76. A method of claims 69-74, wherein the viral disease is a Type II Herpes simplex infection.
77. A method of claims 69-76, wherein the formulation contains about 2.0% imiquimod.
78. A method of claims 69-76, wherein the formulation contains about 2.25% imiquimod.
79. A method of claims 69-76, wherein the formulation contains about 2.5% imiquimod.
80. A method of claims 69-76, wherein the formulation contains about 2.75% imiquimod.
81. A method of claims 69-76, wherein the formulation contains about 3% imiquimod.
82. A method of claims 69-76, wherein the formulation contains about 3.25% imiquimod.
83. A method of claims 69-76, wherein the formulation contains about 3.5% imiquimod.
84. A method of claims 69-76, wherein the formulation contains about 3.75% imiquimod.
85. A method of claims 69-76, wherein the formulation contains about 4.0% imiquimod.
86. A method of claims 69-76, wherein the formulation contains about 4.25% imiquimod.
87. A method of claims 69-76, wherein the formulation contains about 4.5% imiquimod.
88. A method of inducing effective interferon biosynthesis to achieve an antiviral affect with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to a dermatological area of a mammal once per day for fourteen (14) days, followed by no application for fourteen (14) days, followed by again applying an effective amount of the low dose imiquimod formulation to the area once per day for fourteen (14) days for a total of twenty-eight (28) doses, and
allowing said imiquimod to remain in contact with the dermatological area for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve effective interferon biosynthesis inducement and an antiviral effect.
89. A method of inducing effective interferon biosynthesis to achieve an antiviral effect with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to a dermatological area, once per day for twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective amount of the low dose imiquimod formulation to the area affected with the area once per day for twenty one (21) days for a total of forty-two (42) doses, and
allowing said imiquimod to remain in contact with the dermatological area for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve effective interferon biosynthesis inducement and an antiviral effect.
90. A method of inducing effective interferon biosynthesis to achieve an antiviral effect with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to a dermatological area, once per day, each day, for up to about 56 consecutive days or about 8 consecutive weeks, and
allowing said imiquimod to remain in contact with the dermatological area for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve effective interferon biosynthesis inducement and an antiviral effect.
91. A method of claims 88-90, wherein the formulation contains about 2.0% imiquimod.
92. A method of claims 88-90, wherein the formulation contains about 2.5% imiquimod.
93. A method of claims 88-90, wherein the formulation contains about 2.75% imiquimod.
94. A method of claims 88-90, wherein the formulation contains about 3% imiquimod.
95. A method of claims 88-90, wherein the formulation contains about 3.25% imiquimod.
97. A method of claims 88-90, wherein the formulation contains about 3.5% imiquimod.
98. A method of claims 88-90, wherein the formulation contains about 3.75% imiquimod.
99. A method of claims 88-90, wherein the formulation contains about 4.0% imiquimod.
100. A method of claims 88-90, wherein the formulation contains about 425% imiquimod.
101. A method of claims 88-90, wherein the formulation contains about 4.5% imiquimod.
102. A method of claims 88-101, wherein the formulation is selected from the group consisting of a cream, ointment, gel, foam, lotion and adhesive-coated sheet material
103. An imiquimod low dose composition for treating topically or transdermally a dermatological disorder with a shorter duration than currently approved for 5% w/w imiquimod by the Food & Drug Administration (“FDA”), said composition comprising:
(a) imiquimod in an amount selected from the group consisting of 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% by weight based on the total weight of the composition, and
(b) a fatty acid, and optionally,
(c) an emollient,
(d) a thickener,
(e) an antioxidant,
(f) preservative,
(g) a solubilizing agent, and/or
(h) a humectant.
104. A composition of claim 103, wherein the total amount of fatty acid present in the composition is between about 3 percent and about 45 percent by weight based on the total weight of a formulation.
105. A composition of claims 103-105, wherein the formulation is selected from the group consisting of a cream, ointment, gel, foam, lotion and adhesive-coated sheet material.
106. A composition of claims 103-105 for use in accordance with the methods of claims 1-99.
107. A method of inducing effective interferon biosynthesis with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to a dermatological area of a mammal once per day for fourteen (14) days, followed by no application for fourteen (14) days, followed by again applying an effective amount of the low dose imiquimod formulation to the area once per day for fourteen (14) days for a total of twenty-eight (28) doses, to induce effective interferon biosynthesis.
108. A method for inducing effective interferon biosynthesis with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to a dermatological area once per day for twenty-one (21) days, followed by no application for twenty-one (21) days, followed by again applying an effective amount of the low dose imiquimod formulation to an area affected with actinic keratosis once per day for twenty-one (21) days for a total of forty-two (42) doses, to induce effective interferon biosynthesis.
109. A method of inducing effective interferon biosynthesis with low dose imiquimod therapy for a shorter duration than currently approved for 5% imiquimod by the Food & Drug Administration (“FDA”), said method comprising:
applying an effective imiquimod dose of a low dose imiquimod formulation, such as about 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% imiquimod % w/w, to a dermatological area once per day each day, for up to 56 consecutive days or about 8 consecutive weeks to induce effective interferon biosynthesis.
110. A method of claims 107-109, wherein the formulation contains about 2.75% imiquimod.
111. New A method of claims 107-109, wherein the formulation contains about 3% imiquimod.
112. A method of claims 107-109, wherein the formulation contains about 3.25% imiquimod.
113. A method of claims 107-109, wherein the formulation contains about 3.5% imiquimod.
114. A method of claims 107-109, wherein the formulation contains about 3.75% imiquimod.
115. A method of claims 107-109, wherein the formulation contains about 4.0% imiquimod.
116. A method of claims 107-109, wherein the formulation contains about 4.25% imiquimod.
117. A method of claims 107-109, wherein the formulation contains about 4.5% imiquimod.
118. A method of claims 107-109 wherein the formulation contains about 2.5% imiquimod.
Descripción
    FIELD OF THE INVENTION
  • [0001]
    This invention pertains to methods and pharmaceutical formulations for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, i.e., imiquimod. More particularly, it pertains to creams, ointments, foams, gels, lotions, pressure sensitive adhesive coatings and adhesive-coated sheet materials, which contain low dose imiquimod, that enhance skin penetration of drugs to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and external genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
  • BACKGROUND
  • [0002]
    The compound I-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, known as imiquimod and commercially marketed in the U.S. under the brand name Aldara®, is disclosed in U.S. Pat. No. 4,689,338 and described therein as an antiviral agent and as an interferon inducer, which is incorporated herein by reference in its entirety. A variety of formulations for topical administration of imiquimod are also described therein. This U.S. Pat. No. 4,689,338 is incorporated herein by reference in its entirety
  • [0003]
    U.S. Pat. No. 4,751,087 discloses the use of a combination of ethyl oleate and glyceryl monolaurate as a skin penetration enhancer for nitroglycerine, with all three components being contained in the adhesive layer of a transdermal patch, wherein this U.S. patent is incorporated herein by reference in its entirety.
  • [0004]
    U.S. Pat. No. 4,411,893 discloses the use of N,N-dimethyldodecylamine-N-oxide as a skin penetration enhancer in aqueous systems, wherein this U.S. patent is incorporated herein by reference in its entirety.
  • [0005]
    U.S. Pat. No. 4,722,941 discloses readily absorbable pharmaceutical compositions that comprise a pharmacologically active agent distributed in a vehicle comprising an absorption-enhancing amount of at least one fatty acid containing 6 to 12 carbon atoms and optionally a fatty acid monoglyceride. Such compositions are said to be particularly useful for increasing the absorption of pharmacologically active bases, wherein this U.S. patent is incorporated herein by reference in its entirety.
  • [0006]
    U.S. Pat. No. 4,746,515 discloses a method of using glyceryl monolaurate to enhance the transdermal flux of a transdermally deliverable drug through intact skin, wherein this U.S. patent is incorporated herein by reference in its entirety.
  • [0007]
    U.S. Pat. No. 5,238,944 discloses topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, wherein this U.S. patent is incorporated herein by reference in its entirety.
  • SUMMARY OF THE INVENTION
  • [0008]
    The present invention provides a substantially non-irritating pharmaceutical formulation for topical and/or transdermal administration of the imiquimod, which formulation comprises:
  • [0009]
    a) 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, i.e., imiquimod, in an amount of about 2 percent to about 4 percent by weight based on the total weight of the formulation; and
  • [0010]
    b) a pharmaceutically acceptable vehicle for imiquimod, which vehicle comprises a fatty acid, such as isostearic acid, linoleic acid, oleic acid, super purified oleic acid (an oleic acid having low polar impurities such as peroxides) and a combination thereof, in a total amount of about 3 percent to about 45 percent by weight based on the total weight of the formulation. The formulation is further characterized in that when tested in the hairless mouse skin model described in U.S. Pat. No. 5,238,944, the formulation provides a penetration of the agent of at least about 10% (and preferably at least about 15%) of the total amount of the agent contained in the formulation in 24 hours.
  • [0011]
    The salient elements of a pharmaceutical formulation according to the invention are (a) imiquimod and (b) a fatty acid, e.g., isostearic, linoleic, super purified oleic or oleic acid and mixtures thereof. A pharmaceutical formulation of the invention can be in any form known to the art, such as a cream, an ointment, a foam, a gel, a lotion or a pressure-sensitive adhesive composition, each form containing the necessary elements in particular amounts and further containing various additional elements.
  • [0012]
    A cream of the invention preferably contains about 2 percent to about 4 percent by weight of imiquimod based on the total weight of the cream; about 5 percent to about 25 percent by weight of fatty acid, based on the total weight of the cream; and optional ingredients such as emollients, emulsifiers, thickeners, and/or preservatives.
  • [0013]
    An ointment of the invention contains an ointment base in addition to imiquimod and fatty acid. An ointment of the invention preferably contains about 2 percent to about 4 percent by weight imiquimod; about 3 percent to about 45 percent, more preferably about 3 percent to about 25 percent by weight fatty acid; and about 40 percent to about 95 percent by weight ointment base, all weights being based on the total weight of the ointment. Optionally, an ointment of the invention can also contain emulsifiers, emollients and thickeners.
  • [0014]
    A pressure-sensitive adhesive composition of the invention contains imiquimod, fatty acid, and an adhesive. The adhesives utilized in a pressure sensitive adhesive composition of the invention are preferably substantially chemically inert to imiquimod. A pressure sensitive adhesive composition of the invention preferably contains about 2 percent to about 4 percent by weight imiquimod; about 10 percent to about 40 percent by weight, more preferably of about 15 percent to about 30 percent by weight, and most preferably about 20 percent to about 30 percent by weight of fatty acid; all weights being based on the total weight of the pressure sensitive adhesive composition.
  • [0015]
    Optionally, pressure sensitive adhesive compositions of the invention can also contain one or more skin penetration enhancers. The total amount of skin penetration enhancer(s) present in a pressure sensitive adhesive composition of the invention is preferably about 3 percent to about 25 percent by weight, and more preferably about 3 percent to about 10 percent by weight based on the total weight of the pressure sensitive adhesive composition.
  • [0016]
    A pressure sensitive adhesive coated sheet material of the invention can be made from a pressure-sensitive adhesive composition of the invention in the form of an article such as a tape, a patch, a sheet, or a dressing.
  • [0017]
    A formulation of the present invention may be used to topically and/or transdermally administer imiquimod for effectively treating viral infections, for example, Type I or Type II Herpes simplex infections, actinic keratosis and superficial basal cell carcinoma for a shorter duration of time and with the same or increased number of applications per week, as compared to current imiquimod topical therapy.
  • [0018]
    For example, a formulation of the present invention containing between greater than about 1% and about 5% imiquimod may be applied from three to seven times per week (once per day) for 8 to 12 weeks to treat viral infections, for example, Type I or Type II Herpes simplex infections, actinic keratosis and superficial basal cell carcinoma or to induce interferon biosynthesis. It should be understood that while formulations of the present invention containing between greater than about 1% and about 5% imiquimod are preferred, formulations containing about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5% are more preferred and that formulations containing about 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75% and 4.0% are most preferred.
  • [0019]
    As to duration, the present invention contemplates applying an effective amount of imiquimod for a shorter period of time than currently approved by the FDA. More specifically, the present invention contemplates applying an effective amount of imiquimod from three to seven times or more per week to an area in need of imiquimod treatment for about 8 to about 12 weeks, and more preferably between about 4, about 5, about 6 and about 7 times a week for about 8, about 9 or about 10 weeks. More preferably, examples of shorter periods of treatment with low dose imiquimod for treating actinic keratosis and warts, e.g., external genital and perianal, as contemplated by the present invention comprise:
  • [0020]
    (a) applying an effective imiquimod dose of the lose dose imiquimod formulations, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, to the area affected with actinic keratosis, as follows: applying an effective amount once per day for fourteen (14) consecutive days, followed by no application for fourteen (14) days, followed by again applying an effective amount once per day for fourteen (14) days for a total of twenty-eight (28) doses to treat actinic keratosis;
  • [0021]
    (b) applying an effective imiquimod dose of the lose dose imiquimod formulations, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, to the area affected with actinic keratosis, as follows: applying an effective amount once per day for twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective amount once per day for twenty one (21) consecutive days for a total of forty-two (42) doses to treat actinic keratosis;
  • [0022]
    (c) applying an effective imiquimod dose of the lose dose imiquimod formulations to the warts, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, once per day, each day, for up to 56 consecutive days or 8 consecutive weeks or until clearance is observed, which ever occurs earlier to treat the warts; or
  • [0023]
    (d) applying an effective imiquimod dose of a lose dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, to a dermatological area, once per day, each day, for:
      • (i) up to about 56 consecutive days or about 8 consecutive weeks to induce effective interferon biosynthesis;
      • (ii) fourteen (14) days, followed by no application for fourteen (14) days, followed by again applying an effective amount imiquimod dose once per day for fourteen (14) consecutive days for a total of twenty-eight (28) doses to induce effective interferon biosynthesis; or
      • (iii) twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective imiquimod dose once per day for twenty one (21) consecutive days for a total of forty-two (42) doses to induce effective interferon biosynthesis.
  • [0027]
    While the present invention has identified what it believes to be preferred concentrations of imiquimod, numbers of applications per week and durations of therapy, it should be understood by those versed in this art that any effective concentration of imiquimod in a formulation and any numbers of application per week that can accomplish a reduction in therapy duration to effectively treat Type I or Type II Herpes simplex infections, actinic keratosis and superficial basal cell carcinoma or induce effective interferon biosynthesis is contemplated by the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0028]
    As used in the specification and claims, the phrase “substantially non-irritating” designates formulations that do not cause unacceptable skin irritation in conventional repeat skin irritation tests in albino rabbits such as that described in Draize et al., “Appraisal of the Safety of Chemicals in Food, Drugs and Cosmetics”, prepared by the Division of Pharmacology of the Food and Drug Administration, published originally in 1959 by the Association of Food and Drug Officials of the United States, Topeka, Kans. (2nd printing 1965), incorporated herein by reference.
  • [0029]
    The present invention provides pharmaceutical formulations such as creams, ointments, foams, gels, lotions and adhesive coatings that contain imiquimod and a fatty acid such as isostearic, linoleic, super purified oleic acid or oleic acid and mixtures thereof. The formulations of the invention provide desirable skin penetrability of the imiquimod.
  • [0030]
    The compound imiquimod is a known antiviral agent that is also known to induce interferon biosynthesis. It can be prepared using the method disclosed in U.S. Pat. No. 4,689,338, the disclosure of which is incorporated herein by reference. The compound can be used to treat viral infections such as Type I or Type II Herpes simplex infections and genital warts. Furthermore, the fact that the compound is an interferon inducer suggests that it, and therefore formulations containing it, might be useful in the treatment of numerous other diseases, such as rheumatoid arthritis, warts, eczema, hepatitis B, psoriasis, multiple sclerosis, essential thrombocythemia, and cancer, such as basal cell carcinoma and other neoplastic diseases. The amount of imiquimod present in a formulation of the invention will be an amount effective to treat the targeted disease state to prevent the recurrence of such a disease or to promote immunity against such a disease. The amount is preferably about 0.5 percent to about 9 percent by weight based on the total weight of a formulation, more preferably between greater than about 1% and about 5% imiquimod, and more preferably between about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% and 4.5%, and most preferred between about 2.75%, 3.0%, 3.25%, 3.5%, 3.75% and 4.0%. Likewise, the shortened period or duration, as contemplated by the present invention, will be for reduced periods of time effective to treat the targeted disease as discussed herein above. By way of example, shorter periods of treatment with low dose imiquimod for treating actinic keratosis and warts, e.g., external genital and perianal, or inducing interferon biosynthesis to achieve an effective antiviral effect, include:
  • [0031]
    (a) applying an effective imiquimod dose of the lose dose imiquimod formulations, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, to the area affected with actinic keratosis, as follows: applying an effective amount once per day for fourteen (14) consecutive days, followed by no application for fourteen (14) days, followed by again applying an effective amount once per day for fourteen (14) days for a total of twenty-eight (28) doses to treat actinic keratosis;
  • [0032]
    (b) applying an effective imiquimod dose of the lose dose imiquimod formulations, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, to the area affected with actinic keratosis, as follows: applying an effective amount once per day for twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective amount once per day for twenty one (21) consecutive days for a total of forty-two (42) doses to treat actinic keratosis;
  • [0033]
    (c) applying an effective imiquimod dose of the lose dose imiquimod formulations to the warts, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, once per day, each day, for up to 56 consecutive days or 8 consecutive weeks or until clearance is observed, which ever occurs earlier to treat the warts; or
  • [0034]
    (d) applying an effective imiquimod dose of a lose dose imiquimod formulation, such as about 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25% or 4.5% imiquimod % w/w, to a dermatological area, once per day, each day, for:
  • [0035]
    (i) up to about 56 consecutive days or about 8 consecutive weeks to induce effective interferon biosynthesis and an antiviral effect;
  • [0036]
    (ii) fourteen (14) days, followed by no application for fourteen (14) days, followed by again applying an effective amount imiquimod to a mammal dose once per day for fourteen (14) consecutive days for a total of twenty-eight (28) doses to induce effective interferon biosynthesis and an antiviral effect; or
  • [0037]
    (iii) twenty one (21) days, followed by no application for twenty one (21) days, followed by again applying an effective imiquimod dose once per day for twenty one (21) consecutive days for a total of forty-two (42) doses to induce effective interferon biosynthesis and an antiviral effect.
  • [0038]
    A fatty acid such as isostearic acid, linoleic acid, refined or super purified oleic acid, unrefined oleic acid blended with effective amounts of antioxidants or mixtures thereof are incorporated into formulations of the present invention. The total amount of fatty acid present in a formulation is preferably between about 3 percent and about 45 percent by weight based on the total weight of a formulation. It should be understood that when oleic acid is selected as a fatty acid, that stability may present issue. Thus, stabilizers, such as anti-oxidants and the like, may be required to preserve pharmaceutical elegance and stability over the life of the oleic acid formulation.
  • [0039]
    A pharmaceutical formulation of the invention can be in a form such as a cream, an ointment, a foam, a gel, a lotion, a pressure-sensitive adhesive composition, or other forms known to those skilled in the art, each particular form containing imiquimod and fatty acid in particular amounts, and optionally containing various additional elements. The preferred amounts of drug and fatty acid, and the amounts and types of optional elements used in formulations of the invention are discussed below with particular reference to creams, ointments and adhesive compositions.
  • [0040]
    A cream according to the invention contains 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine and fatty acid.
  • [0041]
    The amount of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine present in a cream is preferably about 0.5 percent to about 9 percent by weight, and more preferably about 1 percent to about 5 percent by weight, based on the total weight of the cream.
  • [0042]
    The total amount of fatty acid present in a cream of the invention is preferably about 3 percent to about 45 percent by weight, and more preferably about 5 percent to about 25 percent by weight, based on the total weight of the cream.
  • [0043]
    Optionally, a cream of the present invention can contain emollients, emulsifiers, thickeners, and/or preservatives.
  • [0044]
    Emollients such as long chain alcohols, e.g., cetyl alcohol, stearyl alcohol and cetearyl alcohol; hydrocarbons such as petrolatum and light mineral oil; or acetylated lanolin can be included in a cream of the invention. A cream can contain one or more of these emollients. The total amount of emollient in a cream of the invention is preferably about 5 percent to about 30 percent, and more preferably about 5 percent to about 10 percent by weight based on the total weight of the cream.
  • [0045]
    Emulsifiers such as nonionic surface active agents, e.g., polysorbate 60 (available from ICI Americas), sorbitan monostearate, polyglyceryl-4 oleate, and polyoxyethylene(4)lauryl ether or trivalent cationic a cream of the invention. A cream can contain one or more emulsifiers. Generally the total amount of emulsifier is preferably about 2 percent to about 14 percent, and more preferably about 2 percent to about 6 percent by weight based on the total weight of the cream.
  • [0046]
    Pharmaceutically acceptable thickeners, such as Veegum.TM.K (available from R. T. Vanderbilt Company, Inc.), and long chain alcohols (i.e. cetyl alcohol, stearyl alcohol or cetearyl alcohol) can be used. A cream can contain one or more thickeners. The total amount of thickener present is preferably about 3 percent to about 12 percent by weight based on the total weight of the cream.
  • [0047]
    Preservatives such as methylparaben, propylparaben and benzyl alcohol can be present in a cream of the invention. The appropriate amount of such preservative(s) is known to those skilled in the art.
  • [0048]
    Optionally, an additional solubilizing agent such as benzyl alcohol, lactic acid, acetic acid, stearic acid or hydrochloric acid can be included in a cream of the invention.
  • [0049]
    If an additional solubilizing agent is used, the amount present is preferably about 1 percent to about 12 percent by weight based on the total weight of the cream.
  • [0050]
    Optionally, a cream of the invention can contain a humectant such as glycerin, skin penetration enhancers such as butyl stearate, and additional solubilizing agents.
  • [0051]
    It is known to those skilled in the art that a single ingredient can perform more than one function in a cream, i.e., cetyl alcohol can serve both as an emollient and as a thickener.
  • [0052]
    Generally, a cream consists of an oil phase and a water phase mixed together to form an emulsion. Preferably, the amount of water present in a cream of the invention is about 45 percent to about 85 percent by weight based on the total weight of the cream.
  • [0053]
    The oil phase of a cream of the invention can be prepared by first combining the 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine and the fatty acid (if the cream contains benzyl alcohol it can also be added at this point) and heating with occasional stirring to a temperature of about 50° C. to 85° C. When the 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine appears to be completely dissolved, the remaining oil phase ingredients are added and heating is continued until dissolution appears to be complete.
  • [0054]
    The water phase can be prepared by combining all other ingredients and heating with stirring until dissolution appears to be complete.
  • [0055]
    The creams of the invention are generally prepared by adding the water phase to the oil phase with both phases at a temperature of about 65° C. to 75° C. The resulting emulsion is mixed with a suitable mixer apparatus to give the desired cream.
  • [0056]
    An ointment of the invention contains an ointment base in addition to 1-isobutyl-1H-itnidazo[4,5-c]quinolin-4-amine and fatty acid.
  • [0057]
    The amount of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine present in an ointment of the invention is preferably about 0.5 percent to about 9 percent, and more preferably about 0.5 percent to about 5 percent by weight based on the total weight of the ointment.
  • [0058]
    The total amount of fatty acid present in an ointment of the invention is preferably about 3 percent to about 45 percent, and more preferably about 3 percent to about 25 percent based on the total weight of the ointment.
  • [0059]
    A pharmaceutically acceptable ointment base such as petrolatum or polyethylene glycol 400 (available from Union Carbide) in combination with polyethylene glycol 3350 (available from Union Carbide) can be used. The amount of ointment base present in an ointment of the invention is preferably about 60 percent to about 95 percent by weight based on the total weight of ointment.
  • [0060]
    Optionally, an ointment of the invention can also contain emollients, emulsifiers and thickeners. The emollients, emulsifiers, and thickeners and the preferred amounts thereof described above in connection with creams are also generally suitable for use in an ointment of the invention.
  • [0061]
    An ointment according to the invention can be prepared by combining 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine with fatty acid and heating with occasional stirring to a temperature of about 65° C. When the 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine appears to be completely dissolved, the remaining ingredients are added and heated to about 65° C. The resulting mixture is mixed with a suitable mixer while being allowed to cool to room temperature.
  • [0062]
    A pressure-sensitive adhesive composition of the invention contains 1-isobutyl1H-imidazo[4,5-c]-quinolin-4-amine, fatty acid, and a pressure sensitive adhesive polymer.
  • [0063]
    The amount of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine present in a pressure sensitive adhesive composition of the invention is preferably about 0.5 percent to about 9 percent by weight, and more preferably about 3 percent to about 7 percent by weight based on the total weight of the adhesive composition. The amount of fatty acid present is preferably about 10 percent to about 40 percent by weight, more preferably about 15 percent to about 30 percent by weight, and most preferably about 20 percent to about 30 percent by weight, based on the total weight of the adhesive composition.
  • [0064]
    Preferably, the adhesive polymer utilized in a pressure sensitive adhesive composition of the invention is substantially chemically inert to 1-isobutyl-1Himidazo[4,5-c]quinolin-4-amine. The adhesive polymer is preferably present in an amount of about 55 percent to about 85 percent by weight based on the total weight of the composition. Suitable adhesive polymers include acrylic adhesives that contain, as a major constituent (i.e., at least about 80 percent by weight of all monomers in the polymer), a hydrophobic monomeric acrylic or methacrylic acid ester of an alkyl alcohol, the alkyl alcohol containing 4 to 10 carbon atoms. Examples of suitable monomers are those discussed below in connection with the “A Monomer”. These adhesive polymers can further contain minor amounts of other monomers such as the “B Monomers” listed below.
  • [0065]
    Preferred adhesives include acrylic pressure-sensitive adhesive copolymers containing A and B Monomers as follows: Monomer A is a hydrophobic monomeric acrylic or methacrylic add ester of an alkyl alcohol, the alkyl alcohol containing 4 to 10 carbon atoms, preferably 6 to 10 carbon atoms, more preferably 6 to 8 carbon atoms, and most preferably 8 carbon atoms. Examples of suitable A Monomers are n-butyl, n-pentyl, n-hexyl, isoheptyl, n-nonyl, n-decyl, isohexyl, 2-ethyloctyl, isooctyl and 2-ethylhexyl acrylates. The most preferred A Monomer is isooctyl acrylate.
  • [0066]
    Monomer B is a reinforcing monomer selected from the group consisting of acrylic acid; methacrylic acid; alkyl acrylates and methacrylates containing 1 to 3 carbon atoms in the alkyl group; acrylamide; methacrylamide; lower alkyl-substituted acrylamides (i.e., the alkyl group containing 1 to 4 carbon atoms) such as tertiary-butyl acrylamide; diacetone acrylamide; n-vinyl-2-pyrrolidone; vinyl ethers such as vinyl tertiary-butyl ether; substituted ethylenes such as derivatives of maleic anhydride, dimethyl itaconate and monoethyl formate and vinyl perfluoro-n-butyrate. The preferred B Monomers are acrylic acid, methacrylic acid, the above-described alkyl acrylates and methacrylates, acrylamide, methacrylamide, and the above-described lower alkyl substituted acrylamides. The most preferred B Monomer is acrylamide.
  • [0067]
    In one embodiment of a pressure-sensitive adhesive composition of the invention, the pressure-sensitive adhesive copolymer containing A and B Monomers as set forth above preferably contains the A Monomer in an amount by weight of about 80 percent to about 98 percent of the total weight of all monomers in the copolymer. The A Monomer is more preferably present in an amount by weight of about 88 percent to about 98 percent, and is most preferably present in an amount by weight of about 91 percent to about 98 percent. The B Monomer in such a copolymer is preferably present in the pressure-sensitive adhesive copolymer in an amount by weight of about 2 percent to about 20 percent, more preferably about 2 percent to about 12 percent, and most preferably 2 to 9 percent of the total weight of the monomers in the copolymer.
  • [0068]
    In another embodiment of a pressure-sensitive adhesive composition of the invention, the adhesive copolymer comprises about 60 to about 80 percent by weight (and preferably about 70 to about 80 percent by weight) of the above-mentioned hydrophobic monomeric acrylic or methacrylic acid ester of an alkyl alcohol (i.e., Monomer A described above) based on the total weight of all monomers in the copolymer; about 4 to about 9 percent by weight based on the total weight of all monomers in the copolymer of a reinforcing monomer selected from the group consisting of acrylic acid, methacrylic acid, an alkyl acrylate or methacrylate containing 1 to 3 carbon atoms in the alkyl group, acrylamide, methacrylamide, a lower alkyl-substituted acrylamide, diacetone acrylamide and N-vinyl-2-pyrrolidone; and about 15 to about 35 percent by weight (and preferably about 15 to about 25 percent by weight) of vinyl acetate based on the total weight of all monomers in the copolymer. In this embodiment the preferred acrylic or methacrylic acid ester is isooctyl acrylate and the preferred reinforcing monomer is acrylamide.
  • [0069]
    The above described adhesive copolymers are known, and methods of preparation therefor are well known to those skilled in the art, having been described for example, in U.S. Pat. No. 24,906 (Ulrich), the disclosure of which is incorporated herein by reference. The polymerization reaction can be carried out using a free radical initiator such as an organic peroxide (e.g., benzoylperoxide) or an organic azo compound (e.g., azobis(2,4-dimethylpentanenitrile), available under the trade designation “Vazo 52” from DuPont).
  • [0070]
    Since pressure-sensitive adhesives such as those described above are inherently rubbery and tacky and are suitably heat and light stable, there is no need to add tackifiers or stabilizers. However, such can be added if desired.
  • [0071]
    Optionally, a pressure sensitive adhesive composition of the invention can also contain one or more skin penetration enhancers such as glyceryl monolaurate, ethyl oleate, isopropyl myristate, diisopropyl adipate and N,N-dimethyldodecylamine-N-oxide, either as a single ingredient or as a combination of two or more ingredients. The skin penetration enhancer(s) preferably form a substantially homogeneous mixture with the pressure sensitive adhesive polymer or copolymer. The total amount of skin penetration enhancer(s) present in a pressure sensitive adhesive composition of the invention is preferably about 3 percent to about 25 percent by weight, more preferably about 3 percent to about 10 percent by weight based on the total weight of the adhesive composition.
  • [0072]
    When the skin penetration enhancer is a single ingredient, it is preferably a skin penetration enhancer such as isopropyl myristate, diisopropyl adipate, ethyl oleate, or glyceryl monolaurate.
  • [0073]
    When a combination skin penetration enhancer is used, it is preferably a combination such as: ethyl oleate with glyceryl monolaurate; ethyl oleate with N,N-dimethyldodecylamine-N-oxide; glyceryl monolaurate with N,N-dimethyldodecylamineN-oxide; and ethyl oleate with both glyceryl monolaurate and N,N dimethyldodecylamine-N-oxide.
  • [0074]
    A pressure-sensitive adhesive composition of the invention can be prepared by combining dry adhesive, 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, fatty acid, and skin penetration enhancer(s) with an organic solvent. The preferred organic solvents are methanol and ethyl acetate. The total solids content of the adhesive coating is preferably in the range of about 15 percent to about 40 percent, and more preferably in the range of about 20 to about 35 percent based on the total weight of the adhesive coating. The resulting mixture is shaken or mixed for a period of about 20 to 72 hours. When this method is used it is preferred that the 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine be in micronized form (i.e., particle size of 1-2 microns in diameter). Optionally, the mixture can be heated during shaking.
  • [0075]
    In a preferred method, the 1-isobutyl-1H-imidazo-4,5-c]quinolin-4-amine is combined with the fatty acid and shaken at 40° C. until there appears to be complete dissolution. The remaining ingredients are added and the mixture is shaken for a period of about 20 to 72 hours.
  • [0076]
    The pressure-sensitive adhesive compositions described above are preferably coated onto one surface of a suitable backing of sheet material, such as a film, to form a pressure-sensitive adhesive coated sheet material. A pressure-sensitive adhesive coated sheet material of the invention can be prepared by knife coating a suitable release liner to a predetermined uniform thickness with a wet adhesive formulation. This adhesive coated release liner is then dried and laminated onto a backing using conventional methods. Suitable release liners include conventional release liners comprising a known sheet material, such as a polyester web, a polyethylene web, or a polystyrene web, or polyethylene-coated paper, coated with a suitable silicone-type coating such as that available under the trade designation Daubed 164Z, from Daubed Co. The backing can be occlusive, non-occlusive or a breathable film as desired. The backing can be any of the conventional materials for pressure-sensitive adhesive tapes, such as polyethylene, particularly low density polyethylene, linear low density polyethylene, high density polyethylene, randomly-oriented nylon fibers, polypropylene, ethylene-vinylacetate copolymer, polyurethane, rayon and the like. Backings that are layered, such as polyethylene-aluminum-polyethylene composites are also suitable. The backing should be substantially non-reactive with the ingredients of the adhesive coating. The presently preferred backing is low density polyethylene.
  • [0077]
    The pressure-sensitive adhesive coated sheet material of the invention can be made in the form of an article such as a tape, a patch, a sheet, a dressing or any other form known to those skilled in the art.
  • [0078]
    Preferably, an article in the form of a patch is made from an adhesive coated sheet material of the invention and applied to the skin of a mammal. The patch is replaced as necessary with a fresh patch to maintain the particular desired therapeutic effect of the 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine.
  • Inherent Viscosity Measurement
  • [0079]
    The inherent viscosity values reported in the Examples below were obtained by the conventional method used by those skilled in the art. The measurement of the viscosity of dilute solutions of the adhesive, when compared to controls run under the same conditions, clearly demonstrates the relative molecular weights. It is the comparative values that are significant; absolute figures are not required. In the examples, the inherent viscosity values were obtained using a Cannon-Fenske #50 viscometer to measure the flow time of 10 ml of a polymer solution (0.2 g polymer/deciliter tetrahydrofuran, in a water bath controlled at 25° C.). The examples and the controls were run under identical conditions. The test procedure followed and the apparatus used are explained in detail in the Textbook of Polymer Science, F. W. Billmeyer, Wiley-Interscience, 2nd Edition, 1971 under: Polymer chains and their characterization, D. Solution Viscosity and Molecular Size, pp 84-85, the disclosure and textbook of which is incorporated by reference.
  • [0080]
    The following examples are provided to illustrate the invention, but are not intended to be limiting thereof. Parts and percentages are by weight unless otherwise specified. Examples of creams, ointments and pressure sensitive adhesive compositions contemplated by the present invention are described in U.S. Pat. No. 4,689,338 and U.S. Pat. No. 5,238,944, which are incorporated herein by reference in their entireties. Percent modifications for, e.g., imiquimod and vehicle, to generate imiquimod formulations as described herein are likewise contemplated by the present invention. In addition, the formulations described and disclosed in U.S. patent application Ser. No. 11/276,324, are also contemplated by the present invention. Thus, U.S. patent application Ser. No. 11/276,324, is incorporated herein by reference in its entirety.
  • Preparative Method 1 Laboratory Scale Preparation of Isooctylacrylate/Acrylamide Copolymer
  • [0081]
    To a 114 gram narrow-mouth glass bottle were added: 18.6 g isooctyl acrylate, 1.4 g acrylamide, 0.04 g benzoyl peroxide, 27.0 g ethyl acetate and 3.0 g methanol. The solution was purged for thirty five seconds with nitrogen at a flow rate of one liter per minute. The bottle was sealed and placed in a rotating water bath at 55° C. for twenty-four hours to effect essentially complete polymerization. The polymer was diluted with ethyl acetate/methanol (90/10) to 23.2 percent solids and had a measured inherent viscosity of 1.26 dl/g in ethyl acetate.
  • Preparative Method 2 Pilot Plant Scale Preparation of Isooctylacrylate/Acrylamide Copolymer
  • [0082]
    155 kg isooctylacrylate, 11.6 kg acrylamide, 209.1 kg ethyl acetate and 23.2 kg methanol were charged to a clean, dry reactor. Medium agitation was applied. The batch was deoxygenated with nitrogen while heating to an induction temperature of 55° C. 114 g Lucidol.TM.70 initiator (available from Pennwalt Corp.) mixed with 2.3 kg ethyl acetate was charged to the reactor. The temperature was maintained at 55° C. throughout the reaction. After 5.5 hours reaction time, 114 g Lucidol.TM.70 mixed with 2.3 kg ethyl acetate were charged to the reactor. After 9.0 hours reaction time, an additional 114 g Lucidol.TM.70 initiator mixed with 2.3 kg ethyl acetate were charged to the reactor. The reaction was continued until the percent conversion was greater than 98 percent as measured by gas chromatographic evaluation of residual monomer concentration. The resulting polymer solution was diluted to 25-28 percent solids with ethyl acetate/methanol (90/10) and had a measured Brookfield viscosity of 17,000-21,000 centipoises using spindle #4 at 12 rpm. The polymer had a measured inherent viscosity of 1.3-1.4 dllg in ethyl acetate.
  • [0083]
    The above procedure was found to provide a pressure-sensitive adhesive that is equivalent in the practice of the present invention to a pressure-sensitive adhesive prepared according to PREPARATIVE METHOD 1.
  • [0084]
    A 25-30 percent solids solution of the isooctyl acrylate:acrylamide (93:7) adhesive copolymer in ethyl acetate/methanol (90:10) was coated onto a two-sided release liner using a knife-coater and coating at 0.5 mm in thickness. The adhesive-coated laminate was dried first at 82° C. for 3 minutes and then at 116° C. for 3 minutes. The dried adhesive coating was then stripped off the release liner and placed in a glass bottle. The foregoing procedure results in a reduction of the amount of any residual monomer in the adhesive copolymer.
  • Preparative Method 3 Preparation of Isooctyl Acrylate:Acrylamide:Vinyl Acetate (75:5:20) Copolymer
  • [0085]
    The procedure of PREPARATIVE METHOD 1 above acrylate, 8.0 g acrylamide, 32.0 g vinyl acetate, 0.32 g benzoyl peroxide, 216.0 g ethyl acetate and 24.0 g methyl alcohol. The resulting polymer was diluted with the ethyl acetate/methyl alcohol mixture to 21.52% solids. The adhesive polymer had a measured inherent viscosity of 1.40 dl/g in ethyl acetate at a concentration of 0.15 g/dl. Its Brookfield viscosity was 2,300 centipoise.
  • Preparative Method 4 Preparation of Isooctyl Acrylate:Acrylamide:Vinyl Acetate (75:5:20) Copolymer
  • [0086]
    A master batch was prepared by combining 621.0 g of isooctyl acrylate, 41.4 g of acrylamide, 165.6 g of vinyl acetate, 1.656 g of 2,2′-azobis(2,4-dimethylpentanenitrile) (available from the DuPont Company as Vazo.TM.52), 884.52 g of ethyl acetate and 87.48 g of methanol. A 400 g portion of the resulting solution was placed in an amber quart bottle. The bottle was purged for two minutes with nitrogen at a flow rate of one liter per minute. The bottle was sealed and placed in a rotating water bath at 45° C. for twenty-four hours to effect essentially complete polymerization. The copolymer was diluted with 250 g of ethyl acetate/methanol (90/10) to 26.05% solids and had a measured inherent viscosity of 1.27 dl/g in ethyl acetate at a concentration of 0.15 g/dl. Its Brookfield viscosity was 5580 centipoise.
  • Example 1
  • [0087]
    A cream according to the present invention is prepared from the following ingredients:
  • [0000]
    % by Weight Amount
    Oil Phase
    1-Isobuty1-1H-imidazo[4,5-c]- 1.0 40.0 g
    quinolin-4-amine
    Isostearic acid 10.0 400.0 g
    Benzyl alcohol 2.0 80.0 g
    Cetyl alcohol 2.2 88.0 g
    Stearyl alcohol 3.1 124.0 g
    Polysorbate 60 2.55 102.0 g
    Sorbitan monostearate 0.45 18.0 g
    Aqueous Phase
    Glycerin 2.0 80.0 g
    Methylparaben 0.2 8.0 g
    Propylparaben 0.02 0.8 g
    Purified water 76.48 3059.2 g

    The materials listed above were combined according to the following procedure:
  • [0088]
    The glycerin, methylparaben, propylparaben and water were weighed into a 4 liter glass beaker then heated on a hot plate with stirring until the parabens isostearic acid and 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine were weighed into an 8 liter stainless steel beaker and heated on a hot plate until the amine was in solution (the temperature reached 69′C.). The benzyl alcohol, cetyl alcohol, stearyl alcohol, polysorbate 60 and sorbitan monostearate were added to the isostearic acid solution and heated on a hot plate until all material was dissolved (the temperature reached 75° C.). With both phases at approximately the same temperature (65°-75° C.), the water phase was added to the oil phase. The mixture was mixed with a homogenizer for 13 minutes then put into a cool water bath and mixed with a 3 inch propeller for 40 minutes (the temperature was 29° C.). The resulting cream was placed in glass jars.
  • Examples 2-9
  • [0089]
    Using the general method of Example 1, the cream formulations shown in Tables 1 and 2 are prepared.
  • [0000]
    TABLE 1
    % by Weight
    Example
    2 3 4 5
    Oil Phase
    1-Isobuty1-1H-imidazo- 1.0 1.0 1.0 1.0
    [4,5-e]quinolin-4-amine
    Isostearic acid 10.0 10.0 5.0 5.0
    Benzyl alcohol 2.0
    Cetyl alcohol 1.7
    Stearyl alcohol 2.3
    Cetearyl alcohol 6.0 6.0 6.0
    Polysorbate 60 2.55 2.55 2.55 2.55
    Sorbitan monostearate 0.45 0.45 0.45 0.45
    Brij .TM. 30a 10.0
    Aqueous Phase
    Glycerin 2.0 2.0 2.0 2.0
    Methylparaben 0.2 0.2 0.2 0.2
    Propylparaben 0.02 0.02 0.02 0.02
    Purified water 77.78 77.78 82.78 72.78
    Brij .TM. 30 (polyoxyethylene(4) lauryl ether) is available from ICI Americas, Inc.
  • [0000]
    TABLE 2
    % by Weight
    Example
    6 7 8 9
    Oil Phase
    1-Isobuty1-1H-imidazo- 1.0 1.0 1.0 1.0
    r4.5-clquinolin-4-amine
    Isostearic acid 10.0 25.0 10.0 6.0
    Benzyl alcohol 2.0 2.0
    Cetyl alcohol 2.2 1.7
    Stearyl alcohol 3.1 2.3
    Cetearyl alcohol 6.0 6.0
    Polysorbate 60 2.55 3.4 2.55 2.55
    Sorbitan monostearate 0.45 0.6 0.45 0.45
    Brij .TM. 30 10.0
    Aqueous Phase
    Glycerin 2.0 2.0 2.0 2.0
    Methylparaben 0.2 0.2 0.2 0.2
    Propylparaben 0.02 0.02 0.02 0.02
    Purified water 67.78 60.48 79.78 79.78
  • Example 10
  • [0090]
    A cream according to the present invention is prepared from the following ingredients:
  • [0000]
    % by Weight Amount
    Oil Phase
    1-Isobuty1-1H-imidazo[4,5-4- 1.0 3.00 g
    quinolin-4-amine
    Isostearic acid 5.0 15.0 g
    White petrolatum 15.0 45.0 g
    Light mineral oil 12.8 38.4 g
    Aluminum stearate 8.0 24.0 g
    Cetyl alcohol 4.0 12.0 g
    Witconol .TM. 14a 3.0 9.00 g
    Acetylated lanolin 1.0 3.0 g
    Propylparaben 0.063 0.19 g
    Aqueous Phase
    Veegum .TM. Kb 1.0 3.0 g
    Methylparaben 0.12 0.36 g
    Purified water 49.017 147.05 g
    aWitconol .TM. 14 (polyglyceryl4 oleate) is available from Witco Chemical Corp. Organics Division
    bVeegum .TM. K (colloidal magnesium aluminum silicate) is available from R. T. Vanderbilt Company Inc.

    The materials listed above were combined according to the following procedure:
  • [0091]
    The 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine and the isostearic acid were weighed into a glass jar and heated with occasional stirring until the amine was dissolved (the temperature reached 68° C.). To this solution was added, the petrolatum, mineral oil, aluminum stearate, cetyl alcohol, Witconol.TM.14, acetylated lanoline and propylparaben. The mixture was heated to 75° C. In a separate beaker, the methylparaben and water were combined and heated until the paraben dissolved (the temperature reached 61° C.). The Veegum.TM.K was added to the aqueous solution and heated at 75° C. for 30 minutes while mixing with a homogenizer. With both phases at 75° C., the aqueous phase was slowly added to the oil phase while mixing with a homogenizer. Mixing was continued for 30 minutes while maintaining a temperature to about 80° C. The jar was then capped and the formulation was allowed to cool.
  • Example 11
  • [0092]
    An ointment according to the present invention is prepared from the following ingredients.
  • [0000]
    % by Weight Amount
    1-Isobuty1-1H-imidazo[4,5-c]quinolin-4- 1.0 0.20 g
    amine
    Isostearic acid 5.0 1.00 g
    Mineral oil 12.8 2.56 g
    White petrolatum 65.2 13.04 g
    Cetyl alcohol 4.0 0.80 g
    Acetylated lanolin 1.0 0.20 g
    Witconol .TM. 143.0 0.60 g
    Aluminum stearate 8.0 1.60 g

    The materials listed above are combined according to following procedure:
  • [0093]
    The 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine and the isostearic acid were placed in a glass jar and heated with stirring until the amine was dissolved. The remaining ingredients were added and the resulting mixture was heated to 65° C. and then mixed while being allowed to cool to room temperature.
  • Example 12
  • [0094]
    Using the general procedure of Example 11 an ointment containing the following ingredients is prepared.
  • [0000]
    % by Weight Amount
    1-Tsobuty1-1H-imidazo[4,5-c]- 1.0 0.20 g
    quinolin-4-amine
    Isostearic acid 6.0 1.20 g
    Polyethylene Glycol 400 55.8 11.16 g
    Polyethylene Glycol 3350 32.6 6.52 g
    Stearyl alcohol 4.6 0.92 g
  • Examples 13-15
  • [0095]
    Creams of the present invention are prepared using the ingredients shown in Table 3. The Example 1 except that benzyl alcohol was used with the isostearic acid to dissolve the 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine.
  • [0000]
    TABLE 3
    Example
    13 14 15
    % by Weight
    Oil Phase
    1-Isobuty1-1H-imidazo[4,5-4- 5.0 5.0 4.85
    quinolin-4-amine
    Isostearic acid 25.0 25.0 24.3
    Benzyl alcohol 2.0 2.0 1.94
    Cetyl alcohol 2.2 2.2 1.16
    Stearyl alcohol 3.1 3.1 1.75
    Petrolatum 3.0 2.91
    Polysorbate 60 3.4 3.4 4.13
    Sorbitan monostearate 0.6 0.6 0.73
    Stearic acid 9.71
    Aqueous Phase
    Glycerin 2.0 2.0 1.94
    Methylparaben 0.2 0.2 0.19
    Propylparaben 0.02 0.02 0.02
    Purified water 53.48 56.48 46.39
  • Example 16
  • [0096]
    A cream according to the present invention is prepared from the following ingredients:
  • [0000]
    % by Weight Amount
    Oil Phase
    1-Isobuty1-1H-imidazo[4,5-c]- 4.0 0.80 g
    quinolin-4-amine
    Isostearic acid 20.0 4.00 g
    Benzyl alcohol 2.0 0.40 g
    Cetyl alcohol 2.2 0.49 g
    Stearyl alcohol 3.1 0.62 g
    Polysorbate 60 3.4 0.68 g
    Sorbitan monostearate 0.6 0.12 g
    Aqueous Phase
    1-Isobuty1-1H-imidazo[4,5-c]- 1.0 0.2 g
    quinolin-4-amine
    Glycerin 2.0 0.4 g
    85% Lactic acid 1.0 0.22 g
    Methylparaben 0.2 0.04 g
    Propylparaben 0.02 0.004 g
    Purified water 60.48 12.0 g

    The materials listed above are combined according to the following procedure:
  • [0097]
    The isostearic acid and 0.8 g of 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine were combined in a glass jar and heated with stirring until the amine had dissolved. The remaining oil phase ingredients were added to this solution and the mixture was heated to about 70° C. The aqueous phase ingredients were weighed into a separate beaker and heated with stirring until the amine and the parabens had dissolved. With both phases at about 70° C., the water phase was added to the oil phase and mixed with a propeller until the mixture cooled to room temperature.
  • Example 17
  • [0098]
    A mixture of 5.9415 g of the 93:7 isooctyl acrylate:acrylamide adhesive copolymer prepared in PREPARATIVE METHOD 2 above, 1.5126 g isostearic acid, 2.0075 g ethyl oleate, 0.3021 g glyceryl monolaurate, 0.2936 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine (micronized) and 23.7 g of 90:10 ethyl acetate:methanol was placed in a small glass jar. The jar was placed on a horizontal shaker and shaken at room temperature for about 13 hours. The formulation was coated at a thickness of 20 mils onto a 5 mil Daubed 164Z liner. The laminate was oven dried for 3 minutes at 105° F., for 2 minutes at 185° F., and for 2 minutes at 210° F. The resulting adhesive coating contained 59.1 percent 93:7 isooctyl acrylate:acylamide adhesive copolymer, 15.0 percent isostearic acid, 20.0 percent ethyl oleate, 3.0 percent glyceryl monolaurate and 2.9 percent 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine. The material was then laminated with 3 mil low density polyethylene backing and die cut into 2.056 cm.sup.2 patches.
  • Examples 18-20 Pressure-Sensitive Adhesive Coated Sheet Materials Prepared Using Unmicronized 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
  • [0099]
    Using the general method of Example 17 the formulations shown below are prepared. 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine that had been ground with a mortar and pestle was used. The adhesive was the 93:7 isooctyl acrylate:acrylamide copolymer prepared in PREPARATIVE METHOD 1 above. The solvent was 90:10 ethyl acetate:methanol. All formulations were mixed at room temperature.
  • [0000]
    Example
    18 19 20
    1-Isobuty1-1H-imidazo[4,5-0- 5.0 3.0 3.0
    quinolin-4-amine
    Ethyl oleate 5.1 5.0 8.0
    Isostearic acid 10.0 10.0 6.0
    Oleic acid 20.0 20.0 13.0
    Glyceryl monolaurate 1.5 1.5 1.5
    N,N-dimethyldodecylamine- 1.0 1.1 3.0
    N-oxide
    Adhesive 57.4 59.3 65.4
  • Example 21
  • [0100]
    A formulation with the same components in the same proportions as Example 18 is prepared using a different method. The 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine was combined with the oleic and isostearic acids and shaken at 40° C. until there was complete dissolution of the 1-isobutyl-1H-imidazol[4,5-c]quinolin-4-amine. The remaining ingredients were added and shaken a 40° C. for 72 hours. Patches measuring 2.056 cm.sup.2 were prepared by the general method of Example 17.
  • Example 22
  • [0101]
    A mixture of 2.4734 g 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine 3.3315 g isostearic acid and 6.6763 g oleic acid is prepared. To 1.8738 g of the above mixture was added 2.8750 g of the 93:7 isooctyl acrylate:acryamide adhesive copolymer prepared in PREPARATIVE METHOD 2 above, 0.2548 g of ethyl oleate, 0.0510 g N,N-dimethyldodecylamine-N-oxide, 0.0820 g glyceryl monolaurate (from Lauricidin, Inc.) and 14.0457 g of 90:10 ethyl acetate/methanol. The above was shaken for 30 hours at room temperature on a horizontal shaker. Transdermal patches were then prepared generally according to the procedures of Example 17.
  • Example 23
  • [0102]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 23.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 10.00 12.50 25.00 10.00 15.00
    Cetyl alcohol 2.20 2.20 2.70 4.00 4.00
    Stearyl alcohol 3.10 3.10 3.80 2.00 2.00
    White petroleum 5.00 5.00 3.00 3.40 2.80
    Polysorbate 60 3.40 3.40 3.40 3.80 3.00
    Sorbitan 0.60 0.60 0.60 1.00 1.00
    Monostearate
    Glycerin 5.00 5.00 2.00 1.00 3.00
    Xanthan gum 0.50 0.50 0.50 0.30 0.70
    Purified water 65.98 63.48 54.78 70.28 64.28
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.00 2.00 2.00 2.00 2.00
    Total: 100.00 100.00 100.00 100.00 100.00
  • Example 24
  • [0103]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 24.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 15.00 12.50 25.00 15.00 10.00
    Cetyl alcohol 2.20 2.20 2.20 2.00 2.00
    Stearyl alcohol 3.10 3.10 3.10 2.00 2.40
    White petroleum 6.00 5.00 3.00 3.40 2.80
    Polysorbate 60 3.00 3.00 3.40 3.80 3.80
    Sorbitan 1.00 1.00 0.60 0.20 1.00
    Monostearate
    Glycerin 5.00 5.00 2.00 3.00 3.00
    Xanthan gum 1.00 0.50 1.00 0.30 0.30
    Purified water 60.23 63.23 55.23 66.83 70.23
    Benzyl alcohol 1.00 2.00 2.00 1.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.25 2.25 2.25 2.25 2.25
    Total: 100.00 100.00 100.00 100.00 100.00
  • Example 25
  • [0104]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 25.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 15.00 15.00 10.00 20.00 15.00 20.00
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    White petroleum 15.50 3.00 8.50 3.00 6.00 3.00
    Polysorbate 60 3.40 3.40 3.40 3.40 3.00 3.00
    Sorbitan 0.60 0.60 0.60 0.60 1.00 1.00
    Monostearate
    Glycerin 2.00 2.00 5.00 2.00 5.00 3.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.75 0.75
    Purified water 52.98 65.48 61.98 60.48 59.23 59.23
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.50 2.50 2.50 2.50 2.50 2.50
    Total: 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 15.00 15.00 15.00 25.00 12.5 25.00
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.70
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.80
    White petroleum 3.00 6.00 6.00 3.00 5.00 3.00
    Polysorbate 60 3.40 3.40 3.00 3.40 3.00 3.40
    Sorbitan 0.60 0.60 1.00 0.50 1.00 0.60
    Monostearate
    Glycerin 2.00 5.00 5.00 2.00 5.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 65.48 59.48 59.48 55.48 62.98 54.28
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.50 2.50 2.50 2.50 2.50 2.50
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 25.00 15.00 20.00 20.00 20.00 20.00
    Cetyl alcohol 2.20 2.00 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 2.00 3.10 3.10 3.10 3.10
    White petroleum 3.00 3.40 5.00 3.00 5.00 3.00
    Polysorbate 60 3.40 3.80 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.2 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 3.00 2.00 5.00 5.00 2.00
    Xanthan gum 1.00 0.30 0.50 0.50 0.50 0.50
    Purified water 54.98 65.58 58.48 57.48 55.48 60.48
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.50 2.50 2.50 2.50 2.50 2.50
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • Example 26
  • [0105]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 26.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 15.00 18.00 15.00 20.00 12.50
    Cetyl alcohol 2.00 2.00 2.00 2.00 2.20
    Stearyl alcohol 2.00 2.00 2.40 2.40 3.10
    White petroleum 3.40 2.80 3.40 2.80 5.00
    Polysorbate 60 3.00 3.80 3.00 3.00 3.40
    Sorbitan 1.00 1.00 0.20 0.20 0.60
    Monostearate
    Glycerin 3.00 2.00 1.00 3.00 6.00
    Xanthan gum 0.30 0.70 0.70 0.30 0.50
    Purified water 65.08 62.48 67.08 61.08 61.48
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.00 3.00 3.00 3.00 3.00
    Total: 100.00 100.00 100.00 100.00 100.00
  • Example 27
  • [0106]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 27.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 15.00 20.00 15.00 20.00 10.00
    Cetyl alcohol 2.00 2.00 4.00 4.00 2.20
    Stearyl alcohol 2.00 2.40 2.40 2.40 3.10
    White petroleum 3.40 2.80 2.50 3.40 5.00
    Polysorbate 60 3.00 3.00 3.00 3.80 3.40
    Sorbitan 1.00 0.20 1.00 1.00 0.60
    Monostearate
    Glycerin 3.00 3.00 1.00 3.00 5.00
    Xanthan gum 0.30 0.30 0.30 0.70 0.50
    Purified water 64.83 60.83 65.33 57.23 64.73
    Benzyl alcohol 2.00 2.00 2.00 1.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.25 3.25 3.25 3.25 3.25
    Total: 100.00 100.00 100.00 100.00 100.00
  • Example 28
  • [0107]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 28.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 15.00 10.00 12.50 19.00 20.00
    Cetyl alcohol 2.00 2.20 2.20 2.20 2.20
    Stearyl alcohol 2.40 3.10 3.10 3.10 3.10
    White petroleum 3.40 5.00 5.00 3.00 3.00
    Polysorbate 60 3.00 3.40 4.00 3.40 3.40
    Sorbitan 0.20 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 1.00 4.00 5.00 2.00 6.00
    Xanthan gum 0.70 0.50 0.50 0.50 0.50
    Purified water 66.58 65.48 61.38 60.48 56.48
    Benzyl alcohol 2.00 2.00 2.00 2.00 1.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.50 3.50 3.50 3.50 3.50
    Total: 100.00 100.00 100.00 100.00 100.00
  • Example 29
  • [0108]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 29.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 20.00 20.00 25.00 18.75 20.00 21.25
    Cetyl alcohol 4.00 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 2.40 3.10 3.10 3.10 3.10 3.10
    White petroleum 3.40 3.00 3.00 5.00 5.00 3.75
    Polysorbate 60 3.80 3.40 3.40 3.00 3.40 3.40
    Sorbitan 1.00 0.60 0.60 1.00 0.60 0.60
    Monostearate
    Glycerin 3.00 2.00 2.00 5.00 5.00 5.00
    Xanthan gum 0.70 0.50 0.50 0.50 0.50 0.50
    Purified water 55.73 59.23 54.23 55.48 54.23 54.23
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.75 3.75 3.75 3.75 3.75 3.75
    Total: 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 20.00 20.00 20.00 25.00 18.75 25.00
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.70
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.80
    White petroleum 3.00 6.00 6.00 3.00 5.00 3.00
    Polysorbate 60 3.40 3.40 3.00 3.40 3.00 3.40
    Sorbitan 0.60 0.60 1.00 0.50 1.00 0.60
    Monostearate
    Glycerin 2.00 5.00 5.00 2.00 5.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 59.23 53.23 53.23 54.23 55.48 53.03
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.75 3.75 3.75 3.75 3.75 3.75
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 25.00 20.00 20.00 20.00 20.00 21.00
    Cetyl alcohol 2.20 4.00 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 2.40 3.10 3.10 3.10 3.10
    White petroleum 3.00 3.40 5.00 3.00 5.00 5.00
    Polysorbate 60 3.40 3.80 3.40 3.40 3.40 3.40
    Sorbitan 0.60 1.00 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 3.00 2.00 5.00 5.00 5.00
    Xanthan gum 1.00 0.70 0.50 0.50 0.50 0.50
    Purified water 53.73 55.73 57.23 56.23 54.23 53.23
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.75 3.75 3.75 3.75 3.75 3.75
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • Example 30
  • [0109]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 30.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Isostearic Acid 20.00 25.00 22.50 20.00 20.00 22.50
    Cetyl alcohol 2.20 2.70 2.20 4.00 2.20 2.20
    Stearyl alcohol 3.10 3.80 3.10 2.40 3.10 3.10
    White petroleum 6.00 3.00 3.00 3.40 5.00 4.00
    Polysorbate 60 3.00 3.40 3.40 3.80 3.40 3.40
    Sorbitan 1.00 0.60 0.60 1.00 0.60 0.60
    Monostearate
    Glycerin 5.00 2.00 2.00 3.00 2.00 2.00
    Xanthan gum 0.50 0.50 1.00 0.70 0.50 0.50
    Purified water 52.98 52.78 55.98 55.48 56.98 55.48
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 4.00 4.00 4.00 4.00 4.00 4.00
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • Example 31
  • [0110]
    Creams are prepared in accordance with the present invention using the ingredients shown in this Example 31.
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 6.00 6.00 6.00 6.00 6.00 6.00
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.00 2.00 2.00 2.00 2.00 2.00
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 5.75 5.75 5.75 5.75 5.75 5.75
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.25 2.25 2.25 2.25 2.25 2.25
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 5.50 5.50 5.50 5.50 5.50 5.50
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.50 2.50 2.50 2.50 2.50 2.50
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 5.25 5.25 5.25 5.25 5.25 5.25
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 2.75 2.75 2.75 2.75 2.75 2.75
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 5.00 5.00 5.00 5.00 5.00 5.00
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.00 3.00 3.00 3.00 3.00 3.00
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 4.75 4.75 4.75 4.75 4.75 4.75
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.25 3.25 3.25 3.25 3.25 3.25
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 4.50 4.50 4.50 4.50 4.50 4.50
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.50 3.50 3.50 3.50 3.50 3.50
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 4.25 4.25 4.25 4.25 4.25 4.25
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 3.75 3.75 3.75 3.75 3.75 3.75
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 4.00 4.00 4.00 4.00 4.00 4.00
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 4.00 4.00 4.00 4.00 4.00 4.00
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 3.75 3.75 3.75 3.75 3.75 3.75
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 4.25 4.25 4.25 4.25 4.25 4.25
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0000]
    Excipients % w/w % w/w % w/w % w/w % w/w % w/w
    Oleic acid 7.40 7.40 7.40 7.40 7.40
    Stearic acid 3.00 3.00 3.00
    Linoleic acid 25.0
    Oleyl alcohol 10.0 10.0
    Cetyl alcohol 2.20 2.20 2.20 2.20 2.20 2.20
    Stearyl alcohol 3.10 3.10 3.10 3.10 3.10 3.10
    Sorbitol 70% 30.0
    Castor oil 15.0
    Lactic acid 5.00
    Urea 5.00
    White petroleum 3.50 3.50 3.50 3.50 3.50 3.50
    Polysorbate 60 3.40 3.40 3.40 3.40 3.40 3.40
    Sorbitan 0.60 0.60 0.60 0.60 0.60 0.60
    Monostearate
    Glycerin 2.00 2.00 2.00 2.00 2.00 2.00
    Xanthan gum 0.50 0.50 0.50 0.50 0.50 0.50
    Purified water 67.58 60.58 57.58 52.98 52.98 43.58
    Benzyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00
    Methylparaben 0.20 0.20 0.20 0.20 0.20 0.20
    Citric acid 0.13
    monohydrate
    Ammonium 2.00
    hydroxide solution
    Propylparaben 0.02 0.02 0.02 0.02 0.02 0.02
    Imiquimod 4.50 4.50 4.50 4.50 4.50 4.50
    Total 100.00 100.00 100.00 100.00 100.00 100.00
  • [0111]
    It is believed that the creams of the present invention have Hydrophilic lipophilic balance (HLB) values between about 12 and 15, and more preferably between about 12.4 and about 13.4.
Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US4411893 *24 Sep 198225 Oct 1983Minnesota Mining And Manufacturing CompanyTopical medicament preparations
US4689338 *15 Nov 198525 Ago 1987Riker Laboratories, Inc.1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4722941 *31 May 19782 Feb 1988Kali-Chemie Pharma GmbhReadily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4746515 *26 Feb 198724 May 1988Alza CorporationSkin permeation enhancer compositions using glycerol monolaurate
US4751087 *19 Abr 198514 Jun 1988Riker Laboratories, Inc.Transdermal nitroglycerin delivery system
US4929624 *23 Mar 198929 May 1990Minnesota Mining And Manufacturing CompanyOlefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5238944 *3 Mar 199224 Ago 1993Riker Laboratories, Inc.Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5346905 *21 Ago 199213 Sep 1994Minnesota Mining And Manufacturing Company1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines
US5736553 *31 May 19957 Abr 1998Riker Laboratories, Inc.Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US6245776 *7 Ene 200012 Jun 20013M Innovative Properties CompanyFormulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6335030 *21 Mar 19971 Ene 2002Pharmacia & Upjohn AbTransdermally administered dextromethorphan as antitussive agent
US6693113 *27 Jun 200217 Feb 20043M Innovative Properties Company2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]napthyridin-4 amine
US6706728 *10 Sep 200216 Mar 20043M Innovative Properties CompanySystems and methods for treating a mucosal surface
US6894060 *29 Mar 200117 May 20053M Innovative Properties CompanyMethod for the treatment of dermal lesions caused by envenomation
US7038051 *25 Jul 20052 May 20063M Innovative Properties CompanyImidazonaphthyridines
US7179253 *12 Mar 200420 Feb 20073M Innovative Properties CompanyMethod of tattoo removal
US7507703 *21 Sep 200624 Mar 2009John R. WoodwardMethod of cancer screening; method of cancer treatment; and method of diabetes treatment
US7521459 *28 Jul 200321 Abr 2009Metabeauty Inc.Method for treating damaged skin
US7655672 *12 Dic 20082 Feb 20103M Innovative Properties CompanyImmune response modifier formulations containing oleic acid and methods
US7696159 *15 Ene 200813 Abr 2010Graceway Pharmaceuticals, LlcTreatment for basal cell carcinoma
US7699057 *12 Mar 200420 Abr 20103M Innovative Properties CompanyMethods for treating skin lesions
US7893083 *1 May 200822 Feb 2011Eugene MandreaMethod of treating genital herpes
US7902210 *1 Feb 20108 Mar 20113M Innovative Properties CompanyReduction of IMIQUIMOD impurities at two months using refined oleic acid
US7902211 *1 Feb 20108 Mar 20113M Innovative Properties CompanyMethod of inducing interferon biosynthesis
US7902212 *1 Feb 20108 Mar 20113M Innovative Properties CompanyReduction of imiquimod impurities at six months using refined oleic acid
US7902213 *1 Feb 20108 Mar 20113M Innovative Properties CompanyPharmaceutical cream with reduced imiquimod impurities at four months using refined oleic acid
US7902214 *1 Feb 20108 Mar 20113M Innovative Properties CompanyMethod of treating a mucosal and/or dermal associated condition
US7902215 *1 Feb 20108 Mar 20113M Innovative Properties CompanyPharmaceutical creams with reduced imiquimod impurities
US7902216 *1 Feb 20108 Mar 20113M Innovative Properties CompanyPharmaceutical creams with refined oleic acid
US7906524 *1 Feb 201015 Mar 20113M Innovative Properties CompanyPharmaceutical cream having similar or less levels of imiquimod impurity formation as cream with BHA (comparator)
US7906525 *1 Feb 201015 Mar 20113M Innovative Properties CompanyReduction of imiquimod impurities at four months using refined oleic acid
US7906526 *1 Feb 201015 Mar 20113M Innovative Properties CompanyMethod of treating a dermal and/or mucosal associated condition
US7906527 *1 Feb 201015 Mar 20113M Innovative Properties CompanyReduction of imiquimod impurities using refined oleic acid
US7915277 *30 Ene 201029 Mar 20113M Innovative Properties CompanyMethod of treating genital or peri-anal warts
US7923429 *15 Jul 200812 Abr 20113M Innovative Properties CompanyTreatment for CD5+ B cell lymphoma
US7928116 *29 Ene 201019 Abr 20113M Innovative Properties CompanyMethod of treating actinic keratosis
US7928117 *31 Ene 201019 Abr 20113M Innovative Properties CompanyMethod of inducing cytokine biosynthesis
US7928118 *1 Feb 201019 Abr 20113M Innovative Properties CompanyReduction of imiquimod impurities in pharmaceutical creams
US7932429 *26 Dic 200626 Abr 2011SymateseDevice designed for regenerating the human dermis and process for producing said device
US20020147210 *28 Mar 200210 Oct 20023M Innovative Properties CompanyMethods for delaying recurrence of herpes virus symptoms
US20030007939 *20 Feb 20029 Ene 2003Howard MuradPharmaceutical compositions and methods for managing dermatological conditions
US20030072814 *21 Jun 200217 Abr 2003Maibach Howard I.Topical pharmaceutical composition for the treatment of warts
US20030199538 *27 Nov 200223 Oct 20033M Innovative Properties CompanyPharmaceutical formulation comprising an immune response modifier
US20040087614 *28 Jul 20036 May 2004Leslie BaumannMethod for treating damaged skin
US20040180919 *12 Mar 200416 Sep 20043M Innovative Properties CompanyMethods of improving skin quality
US20040181130 *12 Mar 200416 Sep 20043M Innovative Properties CompanyMethods for diagnosing skin lesions
US20040192585 *24 Mar 200430 Sep 20043M Innovative Properties CompanyTreatment for basal cell carcinoma
US20050048072 *25 Ago 20043 Mar 20053M Innovative Properties CompanyImmunostimulatory combinations and treatments
US20050165043 *28 Mar 200528 Jul 20053M Innovative Properties CompanyMethod of treating scarring
US20050232869 *11 Mar 200520 Oct 2005Foamix Ltd.Nonsteroidal immunomodulating kit and composition and uses thereof
US20060105028 *10 Nov 200518 May 2006Jie ZhangSystems and methods for treating warts
US20060105029 *10 Nov 200518 May 2006Jie ZhangInstant patch for dermal drug delivery
US20060195067 *25 Ago 200431 Ago 2006Wolter James TDelivery of immune response modifier compounds
US20060216333 *1 Sep 200428 Sep 2006Miller Richard LMethods related to the treatment of mucosal associated conditions
US20070049518 *31 Ago 20061 Mar 2007Chandler Stephen RNovel method of treatment of inflammatory skin conditions
US20070081962 *6 Oct 200512 Abr 2007Amit MunshiNovel delivery of immune response modifiers for removal of chronic tattoos
US20070123558 *24 Feb 200631 May 2007Statham Alexis SImmune response modifier formulations containing oleic acid and methods
US20070123559 *12 Sep 200631 May 20073M Innovative Properties CompanyPACKAGING FOR 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-c] QUINOLIN-4-AMINE-CONTAINING FORMULATION
US20070134273 *8 Feb 200514 Jun 2007Francois RomagneComposition and method for the treatment of carcinoma
US20070166384 *8 Abr 200519 Jul 2007Zarraga Isidro Angelo EMethods , composition and preparations for delivery of immune response modifiers
US20070190124 *14 Dic 200616 Ago 2007Jie ZhangTwo or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196293 *14 Dic 200623 Ago 2007Jie ZhangCompositions and methods for treating photo damaged skin
US20070196323 *14 Dic 200623 Ago 2007Jie ZhangPolyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US20070196452 *14 Dic 200623 Ago 2007Jie ZhangFlux-enabling compositions and methods for dermal delivery of drugs
US20070196453 *14 Dic 200623 Ago 2007Jie ZhangTwo or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196457 *14 Dic 200623 Ago 2007Jie ZhangTwo or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20080015271 *12 Jul 200717 Ene 2008Stiefel Research Austrialia Pty LtdFatty acid pharmaceutical foam
US20080025929 *17 Feb 200531 Ene 2008Chemaphor, Inc.Topical Formulations for the Treatment of Skin Conditions
US20080125375 *3 Dic 200729 May 2008Taigen Biotechnology Co., Ltd.Protease inhibitors
US20080125485 *15 Ago 200729 May 2008Action MedicinesUse of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US20080145375 *13 Sep 200419 Jun 2008Glaxo Group LimitedVaccination
US20080161328 *26 Sep 20073 Jul 2008Muller George W5-Substituted quinazolinone derivatives and compositions comprising and methods of using the same
US20080187511 *25 Oct 20077 Ago 2008University Of Pittsburgh-Of The CommonwealthOintment for cancer treatment
US20080193487 *6 Oct 200514 Ago 2008Johannes-Gutenberg-Universitaet MainzPreparation for Vaccination, Vaccination Method and Use of a Vaccination Preparation
US20080214615 *14 Sep 20074 Sep 2008Muller George WN-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
US20090018155 *8 Feb 200815 Ene 2009Gregory Jefferson JMethods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US20090041680 *7 Ago 200812 Feb 2009Foamix Ltd.Wax Foamable Vehicle and Pharmaceutical Compositions Thereof
US20090093514 *12 Dic 20089 Abr 20093M Innovative Properties CompanyImmune response modifier formulations containing oleic acid and methods
US20090130029 *21 Nov 200821 May 2009Foamix Ltd.Glycerol ethers vehicle and pharmaceutical compositions thereof
US20090163532 *3 Feb 200625 Jun 2009Coley Pharmaceutical Group, Inc.Aqueous Gel Formulations Containing Immune Response Modifiers
US20090182004 *14 Ene 200916 Jul 2009Gareth WinckleImiquimod formulation
US20090202443 *17 Abr 200913 Ago 20093M Innovative Properties CompanyMethods of improving skin quality
US20090232755 *12 Mar 200917 Sep 2009Leslie BaumannCombination therapies for treating photodamaged skin
US20090246156 *31 Mar 20081 Oct 2009Audrey KuninAnti-acne sunscreen composition
US20100021394 *31 Jul 200928 Ene 2010Chongxi YuHigh penetration prodrug compositions of 1h-imidazo[4,5-c]quinolin-4-amines and 1h-imidazo[4,5-c]quinolin-4-amine-related compounds
US20100056557 *30 Dic 20054 Mar 2010Bernd BenninghoffTreatment for cutaneous metastases
US20100092401 *12 Jul 200715 Abr 2010Graceway Pharmaceuticals, LlcImmune response modifier formulations
US20100096287 *13 Jul 200722 Abr 2010Stoesz James DImmune Response Modifier Compositions and Methods
US20100129439 *22 Abr 200927 May 2010Frank AlexisAdjuvant Incorporation in Immunonanotherapeutics
US20100150869 *14 Sep 200617 Jun 2010Biomas Ltd.Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
US20100180902 *17 Mar 201022 Jul 20103M Innovative Properties CompanyMethods for diagnosing skin lesions
US20100197722 *2 Abr 20105 Ago 2010Graceway Pharmaceuticals, LlcTreatment for basal cell carcinoma
US20100267678 *16 Abr 201021 Oct 2010Zars Pharma, Inc.Flux-enabling compositions and methods for dermal delivery of drugs
US20110021555 *11 Dic 200927 Ene 2011Graceway Pharmaceuticals, LlcLower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses
US20110038900 *28 Abr 200917 Feb 2011Novartis AgNanoparticles for use in pharmaceutical compositions
US20110045037 *1 Dic 200824 Feb 2011Foamix Ltd.Foam containing benzoyl peroxide
US20110135604 *1 Dic 20109 Jun 2011Gilead Sciences, Inc.Antiviral compounds
US20110257216 *8 Jul 201120 Oct 2011Graceway Pharmaceuticals, Llc.2 x 2 x 2 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US859819618 Jul 20123 Dic 2013Medicis Pharmaceutical CorporationMethods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US864261626 Jul 20124 Feb 2014Medicis Pharmaceutical CorporationLower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US907888927 Nov 201314 Jul 2015Medicis Pharmaceutical CorporationLower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US927197327 Nov 20131 Mar 2016Medicis Pharmaceutical CorporationMethods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US93705096 Ago 201221 Jun 2016Medicis Pharmaceutical Corporation2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
US20110207766 *30 Abr 201025 Ago 2011Graceway Pharmaceuticals, Llc.Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
WO2011163617A1 *24 Jun 201129 Dic 2011Graceway Pharmaceuticals, LlcCombination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
WO2013013055A1 *19 Jul 201224 Ene 2013Rubigo Therapeutics, Inc.System for drug delivery and monitoring
Clasificaciones
Clasificación de EE.UU.514/293
Clasificación internacionalA61P17/12, A61P35/00, A61P31/22, A61K31/4745
Clasificación cooperativaA61K9/7061, A61K9/0014, A61K47/12, A61K47/10, A61K31/4745
Clasificación europeaA61K31/4745, A61K47/12, A61K47/10, A61K9/70E2B6B2, A61K9/00M3
Eventos legales
FechaCódigoEventoDescripción
3 Mar 2010ASAssignment
Owner name: GRACEWAY PHARMACEUTICALS, LLC,TENNESSEE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREGORY, JEFFERSON J.;REEL/FRAME:024021/0307
Effective date: 20100225
13 Dic 2011ASAssignment
Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRACEWAY PHARMACEUTICALS, LLC;REEL/FRAME:027370/0813
Effective date: 20111202